Sinopharm Group Co Ltd (1099):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sinopharm Group Co Ltd (1099) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9839
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp is a distributor of pharmaceutical and healthcare products. The group provides distribution, logistics and other value-added services to foreign and domestic manufacturers and suppliers of pharmaceuticals, medical products and supplies and other healthcare products. It also serves hospitals, primary health services institutions and retail drug stores. Sinopharm also manufactures and sells pharmaceuticals, chemical reagents and laboratory supplies, and engages in the innovation of pharmaceutical, medical services and other health-related industries. Besides, the group manages a chain of medicine stores across China through direct operations and franchises to market pharmaceutical and healthcare products. Sinopharm is headquartered in Changning District, Shanghai, China.

Sinopharm Group Co Ltd (1099) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14
Partnerships 15
Chi-Med Forms Joint Venture with Sinopharm 15
Mitsubishi Forms Joint Venture With Sinopharm 16
China NT Pharma To Form Joint Venture With Sinopharm 17
Licensing Agreements 18
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19
Equity Offering 21
Sinopharm Raised USD728 Million in Private Placement of Shares 21
Sinopharm Completes Private Placement Of Shares For US$525 Million 23
Debt Offering 25
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 25
Acquisition 26
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 32
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 33
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 34
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 35
Sinopharm Group Co Ltd – Key Competitors 36
Sinopharm Group Co Ltd – Key Employees 37
Sinopharm Group Co Ltd – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Joint Venture 39
Recent Developments 40
Financial Announcements 40
Jul 31, 2017: Sinopharm Group: Proposed Re – Election And Appointment Of Directors And Supervisors 40
Mar 24, 2017: Sinopharm Group: Annual results announcement for the year ended 31 December 2016 41
Mar 20, 2017: Sinopharm Group: Announcement Preliminary Results of Sinopharm Accord for the Year Ended 31 December 2016 44
Corporate Communications 45
Mar 24, 2017: Sinopharm Group: Change in chairman of the board 45
Other Significant Developments 46
May 31, 2017: Sinopharm Launches New Logo 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sinopharm Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14
Chi-Med Forms Joint Venture with Sinopharm 15
Mitsubishi Forms Joint Venture With Sinopharm 16
China NT Pharma To Form Joint Venture With Sinopharm 17
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18
Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19
Sinopharm Raised USD728 Million in Private Placement of Shares 21
Sinopharm Completes Private Placement Of Shares For US$525 Million 23
Sinopharm Group Plans Public Offering Of Bonds For US$633 Million 25
China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28
Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29
Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31
Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For US$132.6 Million 32
Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For US$6.4 Million 33
China National Accord To Acquire 70% Stake In Guangdong Pharma Company For US$2.14 Million 34
China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For US$5 Million 35
Sinopharm Group Co Ltd, Key Competitors 36
Sinopharm Group Co Ltd, Key Employees 37
Sinopharm Group Co Ltd, Subsidiaries 38
Sinopharm Group Co Ltd, Joint Venture 39

List of Figures
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Sinopharm Group Co Ltd (1099):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atlantia SpA (ATL):企業の財務・戦略的SWOT分析
    Atlantia SpA (ATL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Enercon GmbH-エネルギー分野:企業M&A・提携分析
    Summary Enercon GmbH (Enercon) is a renewable energy equipment company that manufactures and supplies wind energy converters (WEC). It produces components of the WECs including annular generators, inverters, rotor blades, cast components, towers and machine houses. Enercon provides electrical and me …
  • Vitrolife AB (VITR):企業の財務・戦略的SWOT分析
    Summary Vitrolife AB (Vitrolife) is a developer, producer and marketer of laboratory products. The company provides products such as Oocyte retrieval needles, sperm processing, culture media, culture oil, additional culture media, micromanipulation solutions, vitrolife labware, micromanipulation pip …
  • PNE Wind AG (PNE3)-エネルギー分野:企業M&A・提携分析
    Summary PNE Wind AG (PNE) is a renewable energy company. It has a presence in the entire value added chain in the wind energy sector. The company develops, manages projects, realizes, finances, and operates wind-farm projects. PNE also offers commercial and technical operating management services fo …
  • Total Energy Services Inc. (TOT):企業の財務・戦略的SWOT分析
    Total Energy Services Inc. (TOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Millennium Minerals Limited:企業の戦略・SWOT・財務情報
    Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report Summary Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Pinnacle Entertainment Inc:企業のM&A・事業提携・投資動向
    Pinnacle Entertainment Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pinnacle Entertainment Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Robert W. Baird & Co. Private Wealth Management:企業の戦略・SWOT・財務情報
    Robert W. Baird & Co. Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Robert W. Baird & Co. Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Aiphone Co Ltd (6718):企業の財務・戦略的SWOT分析
    Aiphone Co Ltd (6718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析
    Summary MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs such as MN-001, for the treatm …
  • Aselsan Elektronik Sanayi Ve Ticaret A.S.:企業の戦略・SWOT・財務情報
    Aselsan Elektronik Sanayi Ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary Aselsan Elektronik Sanayi Ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • American Shared Hospital Services (AMS):企業の財務・戦略的SWOT分析
    Summary American Shared Hospital Services (ASHS) is a healthcare company that offers medical equipment to hospitals and medical centers. The company offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning an …
  • EVA Airways Corporation:戦略・SWOT・企業財務分析
    EVA Airways Corporation - Strategy, SWOT and Corporate Finance Report Summary EVA Airways Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Florida Keys Electric Cooperative Association, Inc.:発電所・企業SWOT分析
    Florida Keys Electric Cooperative Association, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analys …
  • Eco (Atlantic) Oil & Gas Ltd (EOG):企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • Technical Olympic SA:企業の戦略・SWOT・財務情報
    Technical Olympic SA - Strategy, SWOT and Corporate Finance Report Summary Technical Olympic SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Avon Rubber Plc (AVON):企業の財務・戦略的SWOT分析
    Avon Rubber Plc (AVON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Regency Centers Corporation:企業のM&A・事業提携・投資動向
    Regency Centers Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Regency Centers Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • China Huaneng Group:電力:M&Aディール及び事業提携情報
    Summary China Huaneng Group (CHNG) is a state-owned power generation company. It invests, develops, constructs, operates and manages power sources in China. The company develops coal-fired, hydro, wind, solar, nuclear and natural gas-fired power projects. CHNG also involved in the development, inves …
  • Doosan Heavy Industries & Construction Co Ltd (034020):企業の財務・戦略的SWOT分析
    Doosan Heavy Industries & Construction Co Ltd (034020) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆